Rheological transition driven by matrix makes cancer spheroids resilient under confinement
Life Science Alliance · 2025-06 · 8 (6) · e202402601
DOI: 10.26508/lsa.202402601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 27.03.2025. Verfasst von Tavishi Dutt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Nanoscience and Engineering, Indian Institute of Science, Bangalore, India. Hauptthemen laut MEDLINE: Spheroids, Cellular, Extracellular Matrix, Ovarian Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome Trust/DBT India Alliance, John Templeton Foundation.
Abstract (Originalsprache)
Cancer metastasis through confining peritoneal microenvironments is mediated by spheroids: clusters of disseminated cells. Ovarian cancer spheroids are frequently cavitated; such blastuloid morphologies possess an outer ECM coat. We investigated the effects of these spheroidal morphological traits on their mechanical integrity. Atomic force microscopy showed blastuloids were elastic compared with their prefiguring lumenless moruloid counterparts. Moruloids flowed through microfluidic setups mimicking peritoneal confinement, exhibited asymmetric cell flows during entry, were frequently disintegrated, and showed an incomplete and slow shape recovery upon exit. In contrast, blastuloids exhibited size-uncorrelated transit kinetics, rapid and efficient shape recovery upon exit, symmetric cell flows, and lesser disintegration. Blastuloid ECM debridement phenocopied moruloid traits including lumen loss and greater disintegration. Multiscale computer simulations predicted that higher intercellular adhesion and dynamical lumen make blastuloids resilient. Blastuloids showed higher E-cadherin expression, and their ECM removal decreased membrane E-cadherin localization. E-cadherin knockdown also decreased lumen formation and increased spheroid disintegration. Thus, the spheroidal ECM drives its transition from a labile viscoplastic to a resilient elastic phenotype, facilitating their survival within spatially constrained peritoneal flows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Nanoscience and Engineering, Indian Institute of Science, Bangalore, India.
- Department of Developmental Biology and Genetics, Indian Institute of Science, Bangalore, India.
- Undergraduate Program, Indian Institute of Science, Bangalore, India.
- Shankara Cancer Hospital and Research Centre, India.
- Centre for Nanoscience and Engineering, Indian Institute of Science, Bangalore, India prosenjits@iisc.ac.in.
- Department of Bioengineering, Indian Institute of Science, Bangalore, India.
ORCID-Profile: Jimpi Langthasa, Annapurna Vadaparty, Prosenjit Sen, Ramray Bhat
Förderung
- Wellcome Trust
- Wellcome Trust/DBT India Alliance
- John Templeton Foundation
- Ministry of Electronics and Information Technology
- Indo-French Centre for the Promotion of Advanced Research
Zitieren
APA
Dutt, T., Langthasa, J., Umesh, M., Mishra, S., Bothra, S., Vidhipriya, K., Vadaparty, A., Sen, P., & Bhat, R. (2025). Rheological transition driven by matrix makes cancer spheroids resilient under confinement. Life Science Alliance, 8(6), e202402601. https://doi.org/10.26508/lsa.202402601
Vancouver
Dutt T, Langthasa J, Umesh M, Mishra S, Bothra S, Vidhipriya K, et al. Rheological transition driven by matrix makes cancer spheroids resilient under confinement. Life Science Alliance. 2025;8(6):e202402601. doi:10.26508/lsa.202402601
BibTeX
@article{Dutt2025,
author = {Dutt, Tavishi and Langthasa, Jimpi and Umesh, Monica and Mishra, Satyarthi and Bothra, Siddharth and Vidhipriya, Kottpalli and Vadaparty, Annapurna and Sen, Prosenjit and Bhat, Ramray},
title = {Rheological transition driven by matrix makes cancer spheroids resilient under confinement},
journal = {Life Science Alliance},
year = {2025},
volume = {8},
number = {6},
pages = {e202402601},
doi = {10.26508/lsa.202402601}
}
EUVIMED